Literature DB >> 27755137

Real-world outcomes, complications, and cost of catheter-based ablation for atrial fibrillation: an update.

Andrew C T Ha1, Harindra C Wijeysundera, David H Birnie, Atul Verma.   

Abstract

PURPOSE OF REVIEW: Catheter-based ablation for atrial fibrillation is a useful and effective form of rhythm-control therapy for symptomatic patients. This article reviews the 'real-world' experience on the outcomes, complications, and costs of atrial fibrillation ablation. RECENT
FINDINGS: Currently, real-world outcomes of atrial fibrillation ablation are derived from retrospective analysis of administrative databases or prospective registries from selected centers and patients. The rate of atrial fibrillation recurrence was reported to be as high as 60% and the rate of repeat ablation ranged from ≈10 to 18% within 1 year after ablation. All-cause hospitalizations after atrial fibrillation ablation were frequent, at up to ≈30% within 1 year and with up to half of them related to atrial fibrillation recurrence or repeat procedures. Rates of periprocedural complications were relatively low (≈3%). Female sex was associated with higher risk of complications such as bleeding, vascular injury, and tamponade. Markov models examining the cost-effectiveness of ablation yielded favorable results when success rates of more than 70% were assumed with long time horizons (>5 years).
SUMMARY: The real-world outcomes of atrial fibrillation ablation are sobering. Confirmation of these findings with prospective, population-based, minimally biased studies is needed. There is a critical need to delineate the downstream economic impact of atrial fibrillation ablation on society to justify its continued delivery and growth.

Entities:  

Mesh:

Year:  2017        PMID: 27755137     DOI: 10.1097/HCO.0000000000000348

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  5 in total

Review 1.  Current progress of computational modeling for guiding clinical atrial fibrillation ablation.

Authors:  Zhenghong Wu; Yunlong Liu; Lv Tong; Diandian Dong; Dongdong Deng; Ling Xia
Journal:  J Zhejiang Univ Sci B       Date:  2021-10-15       Impact factor: 3.066

2.  Ten-year outcome of intraoperative treatment of atrial fibrillation using radiofrequency ablation.

Authors:  Nour Boulad; Nicolas W Shammas; Gerald Early; Shauna Roberts; Gail A Shammas; Yuhning Linda Hu; Holly Park; Michael Jerin
Journal:  Ther Clin Risk Manag       Date:  2017-09-19       Impact factor: 2.423

3.  Left Atrial Stiffness, a Marker of Atrial Cardiomyopathy, and Atrial Fibrillation - Relationships and Predictors for Procedure Success after Catheter Ablation.

Authors:  Tan Chen Wu
Journal:  Arq Bras Cardiol       Date:  2019-06-06       Impact factor: 2.000

4.  Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China.

Authors:  Hongtao Wei; Can Cui; Xiangli Cui; Yi Liu; Dandan Li
Journal:  BMC Health Serv Res       Date:  2021-01-28       Impact factor: 2.655

5.  Case report: Artery of Percheron infarction as a rare complication during atrial fibrillation ablation.

Authors:  Xin Xie; Xuecheng Wang; Jinbo Yu; Xiaoqian Zhou; Liya Shi; Jian Zhou; Yizhang Wu; Zijun Chen; Baowei Zhang; Xiaorong Li; Bing Yang
Journal:  Front Cardiovasc Med       Date:  2022-09-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.